CGRP Monoclonal Antibody LY2951742 for the Prevention of Migraine: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study

¹Department of Neurology, Mayo Clinic, Phoenix, AZ, USA;

²NIHR-Wellcome Trust Clinical Research Facility, Kings College London UKand Dept of Neurology, Univ. of California, San Francisco, San Francisco, CA, USA;

³Craniofacial Pain Center (B&W) and Headache & Face Pain Program (TSDM), Brigham & Women's Hospital, Harvard Medical School and Tufts School of Dental Medicine, Boston, MA, USA;

⁴Eli Lilly and Company (retired), Indianapolis, IN, USA;

⁵Arteaus Therapeutics, Cambridge, MA, USA.